Researchers in the Felsher Lab at Stanford University have developed PD-L1 antibody fragment-conjugated nanoparticles to improve upon existing cancer immunotherapies and extend the range of indications to solid tumors.
Researchers at Stanford have developed synthetic derivatives of a natural product, azapodophyllotoxin (AZP), that exhibit remarkable anticancer activities.
Researchers at Stanford have developed methods to identify and treat MYC-driven cancers, including renal cell carcinoma (RCC). RCC is a common, aggressive type of kidney cancer and effective therapeutics are lacking.
Researchers at Stanford have developed methods to classify and treat MYC-driven hematopoietic cancers. The MYC oncogene drives the proliferation and survival of many hematopoietic cancers. These cancers are highly aggressive and do not respond to conventional chemotherapies.
Researchers in Dr. Dean Felsher's lab have generated a murine hepatocellular carcinoma (HCC) cell line with controllable MYC expression. HCC is one of the most common and incurable malignancies.